R01AG080806

Dementia Prevalence, APOE, and Blood-Based Biomarkers of AD in Native American Communities - Project Summary/Abstract

Great advances are underway in the field of dementia. Symptomatic Alzheimer's disease (AD) can be diagnosed with a simple blood test. The number of new dementia patients per capita is shrinking in parallel to public health campaigns to improve brain health. New drugs are emerging that promise to effectively prevent or treat dementing illness. While these breakthroughs in dementia diagnostics, prevention, and treatment are cause for celebration, hardly anything is known about whether these advances will translate to Native American (NA) communities, where very little is known about dementia from a biomedical perspective.

For instance, only two NA at the time of this writing have available blood test data in the AD Neuroimaging Initiative, the largest AD biobank in the United States. Approximately 200 NA have been included in the largest AD consortium in the country out of over 40,000 participants. This lack of knowledge regarding dementia in NA is problematic and portends a widening of already severe health disparities.

The current study's central hypothesis is that American Indians have unique dementia risk factors and a differential effect of APOE E4 - the most significant genetic risk factor for AD. These factors will change the epidemiology of dementia and preclude a "one size fits all" AD blood test using APOE E4. The first goal of the current project is to determine what types of dementia exist among NA tribal nations, which is currently unknown but is a first step to designing and implementing effective brain health policy.

The second goal involves measuring the ancestry-dependent effect of APOE on AD risk and AD biology in NA. AD blood tests utilize the APOE gene along with direct quantification of the toxic proteins associated with AD to determine a positive or negative result. If inherited from a European ancestor, having an APOE E4 allele increases the chances of AD and also increases the probability of a positive AD blood test result. But if a patient inherits their APOE E4 gene from an African ancestor, there is an attenuated impact on accumulation of toxic proteins that define AD. The same neutral relationship between APOE E4 and AD likely applies to NA - preliminary data from our group and others suggest that inheriting an APOE E4 gene from a NA ancestor similarly does not increase the risk of AD.

If an NA individual undergoes an AD blood test and carries an APOE E4 allele, will they receive a life-changing but false diagnosis for a devastating condition? Our study thus will measure the relationship between APOE and AD risk/biology in NA. As APOE is also a centerpiece of personalized medicine, risk/benefit discussions for anti-amyloid therapy, trial eligibility, and the target of genetically guided therapies, this study will provide critical knowledge about the applicability of APOE-based medical advances to NA.

This is the first study to our knowledge that attempts to bring American Indian dementia care into the 21st century and provide a foundation for this understudied group to benefit from the latest advances in diagnosis, prevention, and treatment of dementia.

Regents Of The University Of Minnesota

NOT APPLICABLE

93.866 - Aging Research

National Institute on Aging (NIA) [HHS - NIH]

Minneapolis, Minnesota 554553008 United States

Single Zip Code

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) (PAR-19-070)

Amendment Since initial award the total obligations have increased 403% from $737,599 to $3,712,189.